<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956839</url>
  </required_header>
  <id_info>
    <org_study_id>PGI/AA/EMP/IEC/46/25.7.09</org_study_id>
    <nct_id>NCT00956839</nct_id>
  </id_info>
  <brief_title>Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis</brief_title>
  <official_title>Double-blind Randomized Study to Determine the Efficacy of Intramuscular Vitamin D3 Supplementation in Tropical Calcific Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanjay Gandhi Postgraduate Institute of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanjay Gandhi Postgraduate Institute of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of 2 different doses of intramuscular
      (IM) vitamin D3 as compared to an oral replacement dose in normalizing vitamin D levels in
      the blood of patients with tropical calcific pancreatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tropical calcific pancreatitis (TCP) is a form of chronic pancreatitis unique to developing
      countries. Patients with TCP often have malabsorption leading to nutritional deficiencies. We
      have noted that vitamin D deficiency is common in patients with TCP. The ideal regimen for
      supplementing vitamin D3 in chronic pancreatitis remains unclear and there are no previous
      studies available. High dose oral vitamin D2 has been shown to be ineffective in normalizing
      vitamin D levels in patients with pancreatic insufficiency due to cystic fibrosis.

      Intramuscular (IM) vitamin D3 supplementation in chronic pancreatitis has certain advantages.
      Firstly, decreased and inconsistent absorption from the intestine is avoided. Secondly, IM
      vitamin D3 has a long duration of action (6-12 months). The safety of high-dose IM vitamin D3
      has been proven in previous studies in healthy individuals. Finally, the injection form is
      considerably less expensive as compared to oral vitamin D3.

      The aim of the current prospective double blind study is to compare 2 regimens of high dose
      IM vitamin D3 replenishment with oral vitamin D3 in standard recommended doses in normalizing
      serum vitamin D3 levels in patients with TCP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Serum 25 Hydroxy Vitamin D3 &gt; 30 ng/ml</measure>
    <time_frame>6 months post intervention</time_frame>
    <description>Percentage of patients in each group with serum 25 hydroxy vitamin D &gt;30 ng/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Total Calcium</measure>
    <time_frame>0, 1, 3, 6 months post intervention</time_frame>
    <description>Serum total calcium (mg/dL) at time points 0, 1, 3 and 6 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pancreatitis, Chronic</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IM Vitamin D3 3,00,000 Units single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IM vitamin D3 6,00,000 Units single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral vitamin D3 500 Units/ day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3 (Cholecalciferol)</intervention_name>
    <description>Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose
Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose
Arm 3 - Oral vitamin D3 500 Units/day for 6 months</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>IM vitamin D3 - Inj Arachitol (Solvay, India)</other_name>
    <other_name>Oral vitamin D3 - Tab Cipcal (Cipla, India)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of tropical calcific pancreatitis established by history of
             abdominal pain or diabetes and evidence on ultrasound or CT scan of pancreatic ductal
             dilatation and intra-ductal stones

        Exclusion Criteria:

          -  History of alcohol intake or any secondary cause for chronic pancreatitis
             (hypercalcemia, hypertriglyceridemia, biliary tract stones)

          -  History of hepatic or renal dysfunction or of current intake of drugs such as
             steroids, anticonvulsant drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eesh Bhatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanjay Gandhi Postgraduate Institute of Medical Sciences</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Mann ST, Stracke H, Lange U, Kl√∂r HU, Teichmann J. Vitamin D3 in patients with various grades of chronic pancreatitis, according to morphological and functional criteria of the pancreas. Dig Dis Sci. 2003 Mar;48(3):533-8.</citation>
    <PMID>12757166</PMID>
  </reference>
  <reference>
    <citation>Barman KK, Premalatha G, Mohan V. Tropical chronic pancreatitis. Postgrad Med J. 2003 Nov;79(937):606-15. Review.</citation>
    <PMID>14654569</PMID>
  </reference>
  <reference>
    <citation>Dujsikova H, Dite P, Tomandl J, Sevcikova A, Precechtelova M. Occurrence of metabolic osteopathy in patients with chronic pancreatitis. Pancreatology. 2008;8(6):583-6. doi: 10.1159/000159845. Epub 2008 Sep 29.</citation>
    <PMID>18824882</PMID>
  </reference>
  <reference>
    <citation>Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, Guise TA, Hardin DS, Haworth CS, Holick MF, Joseph PM, O'Brien K, Tullis E, Watts NB, White TB. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005 Mar;90(3):1888-96. Epub 2004 Dec 21. Review.</citation>
    <PMID>15613415</PMID>
  </reference>
  <reference>
    <citation>Boyle MP, Noschese ML, Watts SL, Davis ME, Stenner SE, Lechtzin N. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005 Jul 15;172(2):212-7. Epub 2005 Apr 28.</citation>
    <PMID>15860755</PMID>
  </reference>
  <reference>
    <citation>Green D, Carson K, Leonard A, Davis JE, Rosenstein B, Zeitlin P, Mogayzel P Jr. Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr. 2008 Oct;153(4):554-9. doi: 10.1016/j.jpeds.2008.04.058. Epub 2008 Jun 27.</citation>
    <PMID>18589445</PMID>
  </reference>
  <reference>
    <citation>Lark RK, Lester GE, Ontjes DA, Blackwood AD, Hollis BW, Hensler MM, Aris RM. Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am J Clin Nutr. 2001 Mar;73(3):602-6.</citation>
    <PMID>11237938</PMID>
  </reference>
  <reference>
    <citation>Diamond TH, Ho KW, Rohl PG, Meerkin M. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust. 2005 Jul 4;183(1):10-2.</citation>
    <PMID>15992330</PMID>
  </reference>
  <reference>
    <citation>Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999 May;69(5):842-56. Review.</citation>
    <PMID>10232622</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <results_first_submitted>July 23, 2012</results_first_submitted>
  <results_first_submitted_qc>February 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2013</results_first_posted>
  <last_update_submitted>February 10, 2013</last_update_submitted>
  <last_update_submitted_qc>February 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sanjay Gandhi Postgraduate Institute of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Eesh Bhatia</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Tropical calcific pancreatitis</keyword>
  <keyword>Tropical chronic pancreatitis</keyword>
  <keyword>Chronic pancreatitis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Intramuscular vitamin D3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from Endocrinology and Gastroenterology Clinics of Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow from July 2009 to December 2009</recruitment_details>
      <pre_assignment_details>All patients who consented for the study were enrolled and randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IM Vitamin D3 3,00,000 Units</title>
          <description>IM Vitamin D3 3,00,000 Units single dose</description>
        </group>
        <group group_id="P2">
          <title>IM Vitamin D3 6,00,000 Units</title>
          <description>IM vitamin D3 6,00,000 Units single dose</description>
        </group>
        <group group_id="P3">
          <title>Oral Vitamin D3</title>
          <description>Oral vitamin D3 500 Units/ day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IM Vitamin D3 3,00,000 Units</title>
          <description>IM Vitamin D3 3,00,000 Units single dose</description>
        </group>
        <group group_id="B2">
          <title>IM Vitamin D3 6,00,000 Units</title>
          <description>IM vitamin D3 6,00,000 Units single dose</description>
        </group>
        <group group_id="B3">
          <title>Oral Vitamin D3</title>
          <description>Oral vitamin D3 500 Units/ day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="8.9"/>
                    <measurement group_id="B2" value="33.9" spread="10.6"/>
                    <measurement group_id="B3" value="34.3" spread="9.2"/>
                    <measurement group_id="B4" value="33" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Serum 25 Hydroxy Vitamin D3 &gt; 30 ng/ml</title>
        <description>Percentage of patients in each group with serum 25 hydroxy vitamin D &gt;30 ng/ml</description>
        <time_frame>6 months post intervention</time_frame>
        <population>Intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>IM Vitamin D3 3,00,000 Units</title>
            <description>IM Vitamin D3 3,00,000 Units single dose</description>
          </group>
          <group group_id="O2">
            <title>IM Vitamin D3 6,00,000 Units</title>
            <description>IM vitamin D3 6,00,000 Units single dose</description>
          </group>
          <group group_id="O3">
            <title>Oral Vitamin D3</title>
            <description>Oral vitamin D3 500 Units/ day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Serum 25 Hydroxy Vitamin D3 &gt; 30 ng/ml</title>
          <description>Percentage of patients in each group with serum 25 hydroxy vitamin D &gt;30 ng/ml</description>
          <population>Intention to treat analysis</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="75.1" upper_limit="94.9"/>
                    <measurement group_id="O2" value="29" lower_limit="16.9" upper_limit="41.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Total Calcium</title>
        <description>Serum total calcium (mg/dL) at time points 0, 1, 3 and 6 months</description>
        <time_frame>0, 1, 3, 6 months post intervention</time_frame>
        <population>at time points 0, 1, 3 and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>IM Vitamin D3 3,00,000 Units</title>
            <description>IM Vitamin D3 3,00,000 Units single dose</description>
          </group>
          <group group_id="O2">
            <title>IM Vitamin D3 6,00,000 Units</title>
            <description>IM vitamin D3 6,00,000 Units single dose</description>
          </group>
          <group group_id="O3">
            <title>Oral Vitamin D3</title>
            <description>Oral vitamin D3 500 Units/ day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Calcium</title>
          <description>Serum total calcium (mg/dL) at time points 0, 1, 3 and 6 months</description>
          <population>at time points 0, 1, 3 and 6 months</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.20" spread="0.48" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="9.56" spread="0.48" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="9.24" spread="0.48" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.28" spread="0.44"/>
                    <measurement group_id="O2" value="9.52" spread="0.40"/>
                    <measurement group_id="O3" value="9.28" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" spread="0.52"/>
                    <measurement group_id="O2" value="9.44" spread="0.48"/>
                    <measurement group_id="O3" value="9.40" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" spread="0.60"/>
                    <measurement group_id="O2" value="9.40" spread="0.60"/>
                    <measurement group_id="O3" value="9.28" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IM Vitamin D3 3,00,000 Units</title>
          <description>IM Vitamin D3 3,00,000 Units single dose</description>
        </group>
        <group group_id="E2">
          <title>IM Vitamin D3 6,00,000 Units</title>
          <description>IM vitamin D3 6,00,000 Units single dose</description>
        </group>
        <group group_id="E3">
          <title>Oral Vitamin D3</title>
          <description>Oral vitamin D3 500 Units/ day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Eesh Bhatia</name_or_title>
      <organization>Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow</organization>
      <phone>00915222494382</phone>
      <email>ebhatia@sgpgi.ac.in</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

